Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Rating of "Buy" from Analysts

Key Points

• Dyne Therapeutics, Inc. (NASDAQ:DYN) has received an average analyst rating of "Buy" from sixteen research firms, with three firms issuing a strong buy rating.
• CEO John Cox acquired 100,000 shares of company stock at $9.11 per share, raising his total ownership by 70.33%.
• The company's stock price has fluctuated between a 12-month low of $6.36 and a high of $35.90, currently trading at $12.65.

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) have been given an average recommendation of "Buy" by the sixteen research firms that are covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and three have issued a strong buy rating on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $34.0667.

Several equities research analysts recently issued reports on DYN shares. Raymond James Financial raised shares of Dyne Therapeutics from an "outperform" rating to a "strong-buy" rating and lifted their price objective for the company from $31.00 to $35.00 in a research note on Monday, August 25th. Oppenheimer dropped their price target on Dyne Therapeutics from $34.00 to $13.00 and set an "outperform" rating on the stock in a research report on Wednesday, August 6th. Stifel Nicolaus reduced their price target on shares of Dyne Therapeutics from $66.00 to $36.00 and set a "buy" rating for the company in a report on Thursday, July 31st. Royal Bank Of Canada cut their price objective on shares of Dyne Therapeutics from $25.00 to $23.00 and set an "outperform" rating for the company in a research report on Tuesday, July 29th. Finally, Robert W. Baird decreased their price objective on Dyne Therapeutics from $46.00 to $32.00 and set an "outperform" rating on the stock in a report on Wednesday, June 18th.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, CEO John Cox acquired 100,000 shares of Dyne Therapeutics stock in a transaction dated Monday, July 14th. The stock was bought at an average cost of $9.11 per share, with a total value of $911,000.00. Following the acquisition, the chief executive officer owned 242,179 shares of the company's stock, valued at approximately $2,206,250.69. The trade was a 70.33% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 20.77% of the company's stock.

Hedge Funds Weigh In On Dyne Therapeutics

Several institutional investors have recently bought and sold shares of DYN. Ameritas Investment Partners Inc. boosted its stake in Dyne Therapeutics by 11.1% in the second quarter. Ameritas Investment Partners Inc. now owns 9,582 shares of the company's stock worth $91,000 after purchasing an additional 955 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Dyne Therapeutics by 5.2% in the first quarter. China Universal Asset Management Co. Ltd. now owns 22,690 shares of the company's stock valued at $237,000 after buying an additional 1,115 shares during the last quarter. Arizona State Retirement System lifted its position in Dyne Therapeutics by 9.2% during the 1st quarter. Arizona State Retirement System now owns 17,501 shares of the company's stock worth $183,000 after buying an additional 1,481 shares in the last quarter. Caxton Associates LLP grew its holdings in Dyne Therapeutics by 10.9% during the 2nd quarter. Caxton Associates LLP now owns 16,599 shares of the company's stock worth $158,000 after acquiring an additional 1,627 shares during the last quarter. Finally, CWM LLC increased its position in Dyne Therapeutics by 168.1% in the 2nd quarter. CWM LLC now owns 3,030 shares of the company's stock valued at $29,000 after acquiring an additional 1,900 shares in the last quarter. Institutional investors own 96.68% of the company's stock.

Dyne Therapeutics Trading Up 2.3%

Shares of NASDAQ:DYN opened at $12.65 on Wednesday. The firm has a fifty day moving average of $12.22 and a two-hundred day moving average of $11.19. The company has a quick ratio of 16.83, a current ratio of 16.83 and a debt-to-equity ratio of 0.17. Dyne Therapeutics has a 12-month low of $6.36 and a 12-month high of $35.90. The firm has a market capitalization of $1.80 billion, a P/E ratio of -3.28 and a beta of 1.10.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings data on Monday, July 28th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.99) by $0.02. On average, equities analysts expect that Dyne Therapeutics will post -3.44 EPS for the current fiscal year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.